Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 48.50
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

9 Jun 2020 07:00

RNS Number : 3194P
Cambridge Cognition Holdings PLC
09 June 2020
 

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Grant of Options

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 8 June 2020, the Company granted options ("Options") over a total of 1,040,041 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and the Company's unapproved option scheme.

Of these Options:

- 688,020 were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company;

Name

Role

Number of Options Granted

Total number of Options held following Grant

Total number of Ordinary Shares

currently held

Percentage of Current Issued Share Capital currently held

Matthew Stork

Chief Executive Officer

196,429

529,287

125,000

0.40%

Nicholas Walters

Chief Financial Officer

60,000

60,000

300,826

0.97%

Jennifer Barnett

Chief Scientific Officer

66,365

182,865

7,213

Under 0.01%

Ricky Dolphin

Chief Technology Officer

93,521

240,634

-

-

Fiona Cree

Chief Operating Officer

76,500

156,857

-

-

Richard Cooper

Chief Commercial Officer

111,786

111,786

-

-

Malcolm Gates

Director of Group Finance

83,419

199,206

-

-

 

- 352,021 were granted to other employees of the Company.

Of the Options granted to PDMRs:

1. 641,429 are exercisable at a price of 28 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 77.5 pence, with the price on the last day of that period being at least 70 pence, and the last day of this period being no later than 31 May 2023; and

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 115 pence, with the price on the last day of that period being at least 105 pence, and the last day of this period being no later than 31 May 2023.

2. 45,091 have been issued under a salary sacrifice scheme and are exercisable at a price of 1 pence per Ordinary Share from 1 November 2021 until 31 October 2023. These options were issued in exchange for a portion of salary being sacrificed amounting to £10,043 between May and July 2020.

3. The remaining 1,500 options are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Of the options granted to other employees of the Company:

1. 250,000 are exercisable at a price of 28 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 77.5 pence, with the price on the last day of that period being at least 70 pence, and the last day of this period being no later than 31 May 2023; and

o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 115 pence, with the price on the last day of that period being at least 105 pence, and the last day of this period being no later than 31 May 2023.

2. 97,521 have been issued under a salary sacrifice scheme and are exercisable at a price of 1 pence per Ordinary Share from 1 November 2021 until 31 October 2023. These options were issued in exchange for a portion of salary being sacrificed amounting to £24,199 between May and July 2020.

3. The remaining 4,500 options are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 2,220,219, representing approximately 7.12% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Jennifer Barnett - Chief Scientific Officer

Fiona Cree - Chief Operating Officer

Ricky Dolphin - Chief Technology Officer

Richard Cooper - Chief Commercial Officer

Malcolm Gates - Director of Group Finance

Nicholas Walters - Chief Financial Officer

Matthew Stork - Chief Executive Officer

2.

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 8 June 2020

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - 196,429 Options

Nicholas Walters - 60,000 Options

Jennifer Barnett - 66,365 Options

Ricky Dolphin - 93,521 Options

Fiona Cree - 76,500 options

Richard Cooper - 111,786 Options

Malcolm Gates - 83,419 Options

d)

Aggregated information:

· Aggregated volume

· Price

n/a

e)

Date of the transaction

8 June 2020

f)

Place of the transaction

Outside a trading venue

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Enquiries

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Nick Walters, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Tel: 020 7220 0500

Geoff Nash / Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

IFC Advisory Limited (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDVLFBBQLBBBE
Date   Source Headline
16th Mar 20167:00 amRNSTrading Update
1st Mar 20167:00 amRNSWearables partnership
15th Feb 20167:00 amRNSDirectorate Change
8th Dec 20157:00 amRNSNew medical device
20th Nov 20157:00 amRNSYear End Trading Update
8th Oct 20157:00 amRNSTwo software licence agreements
21st Sep 20157:00 amRNSFormation of Cantab Corporate Health Limited
10th Sep 20157:00 amRNSHalf Yearly Report
9th Sep 20157:00 amRNSNew patent application
20th Aug 20157:00 amRNSNotice of Results
22nd Jul 20152:30 pmRNSNew research delivered at AAIC
9th Jul 201512:08 pmRNSDirector dealing and Grant of Options
8th Jul 20155:15 pmRNSRe: Directorate Change
1st Jul 201512:00 pmRNSAppointment of Chief Operating Officer
8th Jun 20158:53 amRNSDirector dealing
2nd Jun 201510:30 amRNSAppointment of Non-Executive Director
27th May 201510:33 amRNSResult of AGM
27th May 20157:00 amRNSAGM Statement
21st May 20153:17 pmRNSIssue of Equity
20th May 20157:00 amRNSNew cognitive assessment product
12th May 20157:01 amRNSInvestor teach-in
6th May 20159:35 amRNSHolding(s) in Company
6th May 20157:02 amRNSNew Applications in Healthcare
1st May 201512:02 pmRNSPosting of Annual Report & Notice of AGM
14th Apr 20157:00 amRNSSales of Cantab Connect iPad product exceed £1m
12th Mar 20157:00 amRNSFinal Results
4th Mar 20157:00 amRNSUS office opened
3rd Mar 20157:00 amRNSNotice of Results
21st Jan 20157:00 amRNSLaunch of new iPad research product
16th Dec 20143:12 pmRNSHolding(s) in Company
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.